AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Adjusted Cost of Products Sold — Non-GAAP by Year
Adjusted Cost of Products Sold — Non-GAAP ($M) ($M)
AbbVie Adjusted Cost of Products Sold — Non-GAAP: $21,692M in FY2025, up 142.4% from a year earlier.
Latest, FY2025
21,692
Period ended Dec 31, 2025
Change on a year earlier
+142.4%
8,947 in FY2024
History
4 years
Since FY2022
Sources
4
Documents cited below
Where the FY2025 figure comes from
“|| As adjusted (non-GAAP) | $ | 21,692 | $ | 3,901 | 18.0 | % 11AbbVie Inc.”
Source: Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Reported in Form 8-K Non-GAAP Reconciliations.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Adjusted Cost of Products Sold — Non-GAAP ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21,692 | +142.4% | Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗ |
| FY2024 | Dec 31, 2024 | 8,947 | +3.5% | Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗ |
| FY2023 | Dec 31, 2023 | 8,646 | +0.4% | Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗ |
| FY2022 | Dec 31, 2022 | 8,613 | – | Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗ |
Cite this data
StockData. (2026). AbbVie Adjusted Cost of Products Sold — Non-GAAP ($M), annual FY2022–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/nongaap-adj-cogs
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.